Rona J Hu, MD
Psychiatry · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Hu’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G74426 · Current
Licensed to practise in California · since 1992 · expires 2027-12-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$45,667
Medicare paid this office $45,667 for 35 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 33 | $18,223 | $114 |
| Long return visit (40+ min) | 15 | $12,301 | $171 |
| Psychotherapy with evaluation and management visit, 30 minutes | 32 | $11,550 | $64 |
Who their Medicare patients are
35 Original Medicare patients in 2024. Average age 61 · Under 65 49% · Women 63% · Also on Medicaid 40% · Health risk score 1.06. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: High blood pressure 49%.
The office billed $192,020, Medicare allowed $60,733 and paid $45,667; for 470 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 35 | 470 | 61 | 1.06 | $192,020 | $45,667 |
| 2023 | 41 | 517 | 55 | 1.14 | $188,247 | $37,736 |
| 2022 | 26 | 331 | 50 | 1.19 | $130,667 | $24,105 |
| 2021 | 38 | 390 | 55 | 1.24 | $142,443 | $28,395 |
| 2020 | 26 | 276 | 55 | 0.85 | $110,051 | $16,657 |
| 2019 | 44 | 365 | 52 | 1.23 | $113,068 | $26,198 |
| 2018 | 48 | 415 | 47 | 1.37 | $69,269 | $27,123 |
| 2017 | 50 | 480 | 52 | 1.24 | $88,385 | $30,475 |
| 2016 | 54 | 520 | 54 | 1.62 | $105,906 | $33,542 |
| 2015 | 45 | 461 | 47 | 1.20 | $92,254 | $30,138 |
| 2014 | 58 | 634 | 50 | 1.42 | $140,935 | $44,405 |
| 2013 | 67 | 658 | 45 | 1.18 | $135,789 | $37,078 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 31 | $10,856 | $115 |
| Long return visit (40+ min) | 24 | $10,004 | $172 |
| Psychotherapy with evaluation and management visit, 30 minutes | 37 | $7,433 | $61 |
| Telehealth originating site facility fee | 39 | $3,727 | $22 |
2022: 3 services
| Return visit (30+ min) | 18 | $9,276 | $113 |
| Psychotherapy with evaluation and management visit, 30 minutes | 18 | $5,216 | $61 |
| Telehealth originating site facility fee | 19 | $1,873 | $22 |
2021: 5 services
| Return visit (30+ min) | 19 | $9,495 | $119 |
| Psychotherapy with evaluation and management visit, 30 minutes | 21 | $4,519 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $4,105 | $95 |
| Long return visit (40+ min) | 15 | $3,783 | $172 |
| Telehealth originating site facility fee | 23 | $2,270 | $22 |
2020: 3 services
| Return visit (30+ min) | 20 | $7,965 | $92 |
| Psychotherapy with evaluation and management visit, 30 minutes | 20 | $5,210 | $56 |
| Telehealth originating site facility fee | 19 | $1,424 | $21 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $6,271 | $66 |
| Return visit (30+ min) | 20 | $5,949 | $104 |
| Psychotherapy with evaluation and management visit, 30 minutes | 20 | $3,711 | $63 |
| Return visit (30+ min) | 20 | $3,241 | $59 |
| Psychotherapy with evaluation and management visit, 30 minutes | 21 | $2,548 | $46 |
2018: 5 services
| Return visit (30+ min) | 22 | $7,918 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $6,843 | $65 |
| Psychotherapy with evaluation and management visit, 30 minutes | 22 | $6,305 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,673 | $92 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,580 | $99 |
2017: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $9,546 | $64 |
| Return visit (30+ min) | 22 | $8,863 | $65 |
| Psychotherapy with evaluation and management visit, 30 minutes | 22 | $7,034 | $51 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,524 | $90 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $8,782 | $63 |
| Return visit (30+ min) | 20 | $8,518 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $7,259 | $90 |
| Psychotherapy with evaluation and management visit, 30 minutes | 21 | $7,060 | $51 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $8,651 | $64 |
| Return visit (30+ min) | 22 | $7,916 | $64 |
| Psychotherapy with evaluation and management visit, 30 minutes | 22 | $6,202 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $5,426 | $92 |
2014: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $14,247 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $11,102 | $92 |
| Return visit (30+ min) | 24 | $8,090 | $63 |
| Psychotherapy with evaluation and management visit, 30 minutes | 23 | $6,599 | $54 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,545 | $97 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $15,049 | $62 |
| Return visit (30+ min) | 23 | $6,623 | $49 |
| Psychotherapy with evaluation and management visit, 30 minutes | 23 | $3,476 | $27 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,638 | $176 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,779 | $119 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,343 | $64 |
Drugs they prescribed that Part D paid
$356,075
Pharmacies billed $356,075 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 691) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
583 generic and 108 brand-name prescriptions · $356,075 in drug cost · 107 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Invega Sustenna | 59 | $154,246 | $2,614 |
| Vraylar | 13 | $19,688 | $1,514 |
| Paliperidone Er | 31 | $10,576 | $341 |
| Clozapine | 41 | $7,748 | $189 |
| Aripiprazole | 60 | $5,375 | $90 |
See all 20 drugs
| Invega Sustenna | 59 | $154,246 | $2,614 |
| Vraylar | 13 | $19,688 | $1,514 |
| Paliperidone Er | 31 | $10,576 | $341 |
| Clozapine | 41 | $7,748 | $189 |
| Aripiprazole | 60 | $5,375 | $90 |
| Clozapine Odt | 23 | $4,603 | $200 |
| Asenapine Maleate | 11 | $3,322 | $302 |
| Divalproex | 18 | $1,015 | $56 |
| Risperidone | 63 | $896 | $14 |
| Hydroxyzine | 32 | $671 | $21 |
| Prazosin | 12 | $640 | $53 |
| Quetiapine | 32 | $419 | $13 |
| Olanzapine | 19 | $416 | $22 |
| Propranolol | 22 | $378 | $17 |
| Sertraline | 21 | $373 | $18 |
| Benztropine Mesylate | 23 | $327 | $14 |
| Haloperidol Decanoate | 12 | $250 | $21 |
| Escitalopram | 15 | $140 | $9 |
| Lorazepam | 25 | $72 | $3 |
| Zolpidem | 11 | $41 | $4 |
Year by year
| 2024 | 691 | 40 | 0% (0) | 16% | $356,075 |
| 2023 | 650 | 38 | 0% (0) | 15% | $333,257 |
| 2022 | 518 | 24 | 0% (0) | 19% | $262,417 |
| 2021 | 415 | 28 | 0% (0) | 25% | $218,441 |
| 2020 | 421 | 29 | 0% (0) | 26% | $235,138 |
| 2019 | 464 | 36 | 0% (0) | 22% | $221,037 |
| 2018 | 528 | 40 | None | 17% | $151,750 |
| 2017 | 418 | 33 | None | 20% | $160,055 |
| 2016 | 574 | 34 | None | 25% | $181,336 |
| 2015 | 502 | 32 | None | None | $182,148 |
| 2014 | 523 | 36 | None | 28% | $129,739 |
| 2013 | 477 | 35 | 0% (0) | 31% | $131,119 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Invega Sustenna | 58 | $158,483 | $2,732 |
| Abilify Maintena | 12 | $34,859 | $2,905 |
| Paliperidone Er | 28 | $18,759 | $670 |
| Clozapine | 36 | $4,034 | $112 |
| Aripiprazole | 30 | $2,498 | $83 |
| Divalproex Sodium Er | 29 | $1,557 | $54 |
| Risperidone | 67 | $1,209 | $18 |
| Quetiapine | 43 | $1,207 | $28 |
| Propranolol | 16 | $1,105 | $69 |
| Olanzapine | 12 | $622 | $52 |
| Benztropine Mesylate | 38 | $547 | $14 |
| Haloperidol Decanoate | 13 | $532 | $41 |
| Divalproex | 26 | $432 | $17 |
| Lithium Carbonate | 12 | $422 | $35 |
| Gabapentin | 12 | $421 | $35 |
| Hydroxyzine | 21 | $353 | $17 |
| Lorazepam | 32 | $314 | $10 |
| Paroxetine | 12 | $191 | $16 |
| Sertraline | 16 | $160 | $10 |
| Haloperidol | 11 | $148 | $13 |
2022: 15 drugs
| Invega Sustenna | 44 | $111,036 | $2,524 |
| Fanapt | 27 | $89,844 | $3,328 |
| Clozapine | 41 | $5,328 | $130 |
| Invega | 11 | $4,376 | $398 |
| Aripiprazole | 24 | $2,463 | $103 |
| Risperidone | 61 | $1,132 | $19 |
| Quetiapine | 43 | $812 | $19 |
| Benztropine Mesylate | 44 | $747 | $17 |
| Gabapentin | 12 | $713 | $59 |
| Divalproex | 29 | $528 | $18 |
| Haloperidol Decanoate | 11 | $396 | $36 |
| Propranolol | 16 | $318 | $20 |
| Lorazepam | 32 | $178 | $6 |
| Hydroxyzine | 12 | $148 | $12 |
| Sertraline | 13 | $75 | $6 |
2021: 15 drugs
| Fanapt | 35 | $84,325 | $2,409 |
| Invega Sustenna | 29 | $63,637 | $2,194 |
| Abilify Maintena | 13 | $33,050 | $2,542 |
| Invega | 12 | $11,895 | $991 |
| Aripiprazole | 28 | $3,833 | $137 |
| Clozapine | 30 | $3,783 | $126 |
| Risperidone | 39 | $1,132 | $29 |
| Divalproex Sodium Er | 14 | $643 | $46 |
| Gabapentin | 12 | $434 | $36 |
| Divalproex | 20 | $429 | $21 |
| Benztropine Mesylate | 42 | $393 | $9 |
| Quetiapine | 16 | $303 | $19 |
| Haloperidol Decanoate | 11 | $228 | $21 |
| Hydroxyzine | 15 | $189 | $13 |
| Lorazepam | 16 | $102 | $6 |
2020: 14 drugs
| Fanapt | 40 | $93,189 | $2,330 |
| Invega Sustenna | 30 | $64,690 | $2,156 |
| Abilify Maintena | 12 | $28,841 | $2,403 |
| Vraylar | 13 | $16,725 | $1,287 |
| Invega | 12 | $14,904 | $1,242 |
| Quetiapine Fumarate Er | 25 | $3,314 | $133 |
| Clozapine | 25 | $3,264 | $131 |
| Aripiprazole | 25 | $1,375 | $55 |
| Divalproex | 26 | $1,167 | $45 |
| Risperidone | 35 | $899 | $26 |
| Gabapentin | 15 | $453 | $30 |
| Benztropine Mesylate | 28 | $343 | $12 |
| Trazodone | 17 | $162 | $10 |
| Lorazepam | 18 | $72 | $4 |
2019: 17 drugs
| Fanapt | 31 | $95,625 | $3,085 |
| Invega Sustenna | 27 | $53,653 | $1,987 |
| Vraylar | 12 | $15,136 | $1,261 |
| Invega | 11 | $12,464 | $1,133 |
| Aripiprazole | 29 | $7,836 | $270 |
| Quetiapine Fumarate Er | 15 | $4,113 | $274 |
| Clozapine | 37 | $3,274 | $88 |
| Risperidone | 27 | $1,388 | $51 |
| Gabapentin | 19 | $357 | $19 |
| Benztropine Mesylate | 32 | $304 | $9 |
| Quetiapine | 15 | $269 | $18 |
| Trazodone | 16 | $131 | $8 |
| Escitalopram | 12 | $127 | $11 |
| Mirtazapine | 12 | $126 | $11 |
| Hydroxyzine | 11 | $89 | $8 |
| Clonazepam | 17 | $49 | $3 |
| Lorazepam | 18 | $37 | $2 |
2018: 16 drugs
| Invega Sustenna | 27 | $56,023 | $2,075 |
| Fanapt | 24 | $48,409 | $2,017 |
| Invega | 14 | $15,631 | $1,116 |
| Aripiprazole | 25 | $10,934 | $437 |
| Clozapine | 73 | $5,215 | $71 |
| Risperidone | 24 | $1,196 | $50 |
| Divalproex Sodium Er | 12 | $870 | $73 |
| Ziprasidone | 13 | $775 | $60 |
| Benztropine Mesylate | 64 | $680 | $11 |
| Gabapentin | 19 | $321 | $17 |
| Hydroxyzine | 18 | $192 | $11 |
| Lorazepam | 35 | $116 | $3 |
| Olanzapine | 11 | $100 | $9 |
| Sertraline | 12 | $66 | $5 |
| Escitalopram | 12 | $54 | $5 |
| Trazodone | 13 | $31 | $2 |
2017: 13 drugs
| Fanapt | 33 | $80,945 | $2,453 |
| Invega Sustenna | 23 | $44,235 | $1,923 |
| Invega | 13 | $13,393 | $1,030 |
| Clozapine | 48 | $3,195 | $67 |
| Aripiprazole | 20 | $2,567 | $128 |
| Ziprasidone | 12 | $966 | $80 |
| Benztropine Mesylate | 45 | $821 | $18 |
| Risperidone | 19 | $775 | $41 |
| Haloperidol | 11 | $624 | $57 |
| Olanzapine | 21 | $310 | $15 |
| Lorazepam | 34 | $218 | $6 |
| Sertraline | 19 | $151 | $8 |
| Paroxetine | 11 | $42 | $4 |
2016: 17 drugs
| Fanapt | 35 | $80,424 | $2,298 |
| Risperdal Consta | 52 | $30,976 | $596 |
| Invega Sustenna | 13 | $18,888 | $1,453 |
| Invega | 13 | $12,291 | $945 |
| Aripiprazole | 28 | $7,932 | $283 |
| Clozapine | 58 | $4,661 | $80 |
| Risperidone | 33 | $1,484 | $45 |
| Ziprasidone | 12 | $1,007 | $84 |
| Benztropine Mesylate | 49 | $815 | $17 |
| Quetiapine | 11 | $810 | $74 |
| Divalproex | 11 | $605 | $55 |
| Lorazepam | 53 | $528 | $10 |
| Haloperidol | 16 | $422 | $26 |
| Gabapentin | 20 | $231 | $12 |
| Olanzapine | 18 | $190 | $11 |
| Sertraline | 36 | $184 | $5 |
| Paroxetine | 17 | $122 | $7 |
2015: 13 drugs
| Fanapt | 34 | $64,805 | $1,906 |
| Risperdal Consta | 52 | $27,366 | $526 |
| Invega | 15 | $18,606 | $1,240 |
| Invega Sustenna | 13 | $17,169 | $1,321 |
| Aripiprazole | 17 | $11,241 | $661 |
| Clozapine | 30 | $2,947 | $98 |
| Risperidone | 34 | $1,506 | $44 |
| Ziprasidone | 11 | $1,121 | $102 |
| Benztropine Mesylate | 51 | $749 | $15 |
| Lorazepam | 50 | $513 | $10 |
| Olanzapine | 25 | $290 | $12 |
| Sertraline | 29 | $197 | $7 |
| Paroxetine | 12 | $91 | $8 |
2014: 16 drugs
| Fanapt | 28 | $29,800 | $1,064 |
| Abilify | 27 | $24,385 | $903 |
| Invega | 16 | $19,905 | $1,244 |
| Risperdal Consta | 34 | $19,260 | $566 |
| Latuda | 14 | $13,071 | $934 |
| Olanzapine | 18 | $3,980 | $221 |
| Clozapine | 37 | $2,429 | $66 |
| Ziprasidone | 12 | $1,323 | $110 |
| Risperidone | 48 | $995 | $21 |
| Fluphenazine | 13 | $919 | $71 |
| Benztropine Mesylate | 45 | $587 | $13 |
| Haloperidol | 14 | $483 | $34 |
| Lorazepam | 57 | $362 | $6 |
| Sertraline | 21 | $238 | $11 |
| Paroxetine | 16 | $174 | $11 |
| Gabapentin | 11 | $97 | $9 |
2013: 13 drugs
| Fanapt | 38 | $31,581 | $831 |
| Abilify | 28 | $22,653 | $809 |
| Invega | 17 | $16,741 | $985 |
| Risperdal Consta | 28 | $16,015 | $572 |
| Olanzapine | 14 | $8,729 | $624 |
| Clozapine | 28 | $3,653 | $130 |
| Risperidone | 23 | $1,131 | $49 |
| Lorazepam | 64 | $653 | $10 |
| Benztropine Mesylate | 42 | $545 | $13 |
| Lithium Carbonate | 19 | $487 | $26 |
| Haloperidol | 13 | $416 | $32 |
| Paroxetine | 19 | $308 | $16 |
| Sertraline | 15 | $116 | $8 |
Money from drug and device companies
$869 in 2025
| 2025 | 6 | 7 | None | $869 |
| 2024 | 3 | 3 | None | $289 |
| 2023 | 3 | 3 | None | $249 |
| 2022 | 3 | 7 | $2,460 | $2,772 |
| 2021 | 1 | 1 | None | $94 |
| 2020 | 1 | 1 | $2,925 | $2,925 |
| 2019 | 4 | 4 | None | $380 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Cobenfy | $246 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $131 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $129 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $125 | 1 payment
|
| Neurocrine BioSciences | Ingrezza | $121 | 1 payment
|
| Alkermes | Lybalvi | $118 | 1 payment
|
See all 7 published payments
| Vanda Pharmaceuticals | Meals · 2025-09-11 | Fanapt | $125 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-09 | Cobenfy | $129 |
| Alkermes | Meals · 2025-07-31 | Lybalvi | $118 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-10 | Caplyta | $129 |
| Otsuka America Pharmaceutical | Meals · 2025-04-30 | Abilify Maintena | $131 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-03 | Cobenfy | $116 |
| Neurocrine BioSciences | Meals · 2025-01-16 | Ingrezza | $121 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $289
| Teva Pharmaceuticals USA | Uzedy | $122 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $118 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $49 | 1 payment
|
2023: $249
| Teva Pharmaceuticals USA | Austedo | $122 | 1 payment
|
| Alkermes | Lybalvi | $97 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $30 | 1 payment
|
2022: $2,772
| Sunovion Pharmaceuticals | Latuda | $2,637 | 4 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Abilify Maintena | $92 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $43 | 2 payments
|
2021: $94
| Iti | Caplyta | $94 | 1 payment
|
2020: $2,925
| Alkermes | None | $2,925 | 1 payment
|
2019: $380
| Teva Pharmaceuticals USA | Austedo | $117 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $106 | 1 payment
|
| Tris Pharma | Dyanavel Xr | $94 | 1 payment
|
| Alkermes | Aristada | $64 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508991597
- Licence
- CA G74426California G74426: Current · expires 2027-12-31
- Trained
- University of California, San Francisco School of Medicine, 1990
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-22
- NPI last updated
- 2024-04-30
- NPI record certified
- 2024-04-30
This is when the NPI record was last certified, not a medical board exam.